An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

The company – led by Google DeepMind Founder Demis Hassabis and formed just over two years ago – will apply its AI ... drug development. “The focus we share on advancing groundbreaking drug ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

In an apparently unprecedented move, Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money.

DeepMind, renowned for its cutting-edge AI research, particularly its Alphafold system, which predicts protein structures, stands poised to revolutionize the field of drug discovery. AI’s ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Eli Lilly said it would acquire a cancer program from Scorpion Therapeutics in a deal worth up to $2.5 billion, as it ...

Scorpion Therapeutics Inc. is selling its lead drug in testing for breast cancer and other advanced solid tumors, to Eli ...